These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 38591901)

  • 1. [Expression of immune checkpoints PD-L1, CTLA4, LAG3 in the microenvironment of colon adenocarcinoma depending on MMR status].
    Naumov SS; Krakhmal NV; Tashireva LA; Vtorushin SV
    Arkh Patol; 2024; 86(2):6-13. PubMed ID: 38591901
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mismatch repair-deficient colorectal cancer: a model of immunogenic and immune cell-rich tumor despite nonsignificant programmed cell death ligand-1 expression in tumor cells.
    Le Flahec G; Badic B; Guibourg B; Doucet L; Bail JP; Marcorelles P; Schick U; Uguen A
    Hum Pathol; 2018 Feb; 72():135-143. PubMed ID: 29208565
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinicopathological and immune characterization of mismatch repair deficient endocervical adenocarcinoma.
    Wu YW; Wei LJ; Yang X; Liang HY; Cai MY; Luo RZ; Liu LL
    Oncologist; 2024 Oct; 29(10):e1302-e1314. PubMed ID: 39110901
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PD-L1 and CD8 are associated with deficient mismatch repair status in triple-negative and HER2-positive breast cancers.
    Hou Y; Nitta H; Parwani AV; Li Z
    Hum Pathol; 2019 Apr; 86():108-114. PubMed ID: 30633926
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevalence of Epstein-Barr Virus Infection and Mismatch Repair Protein Deficiency and the Correlation of Immune Markers in Tibetan Patients with Gastric Cancer.
    Shi J; Yang X; Wang X; Luo Y; Zhou W; Luo H; Bianba Z; Nima Z; Wang Q; Wang H; Liao R; Ciren Q; Li M; Pang J
    Biomed Res Int; 2022; 2022():2684065. PubMed ID: 35734348
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of immune-checkpoint molecules in dMMR/pMMR colorectal cancer by multiplex immunohistochemistry.
    Naumov SS; Tashireva LA; Krakhmal NV; Vtorushin SV
    Clin Transl Oncol; 2024 Sep; ():. PubMed ID: 39240301
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Alteration in the Immune Microenvironment Based on APC Status in MSS/pMMR Colon Cancer.
    Lin H; Cao B
    Dis Markers; 2022; 2022():3592990. PubMed ID: 35937946
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Correlation of clinical, pathologic, and genetic parameters with intratumoral immune milieu in mucinous adenocarcinoma of the colon.
    Neyaz A; Pankaj A; Crabbe A; Rickelt S; Leijssen L; Dinaux A; Taylor M; Shroff SG; Crotty R; Zhang ML; Yilmaz OH; Yılmaz O; Patil DT; Parikh AR; Ting DT; Berger D; Deshpande V
    Mod Pathol; 2022 Nov; 35(11):1723-1731. PubMed ID: 35590108
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Programmed death-ligand 1 expression in the immune compartment of colon carcinoma.
    Yılmaz O; Pankaj A; Neyez A; Rickelt S; Taylor M; Lang ER; Leijsen L; Dinaux A; Shroff SG; Crotty R; Zhang ML; Cerda S; Zhao Q; Ferrone C; Ting DT; Patil DT; Yilmaz O; Berger D; Deshpande V
    Mod Pathol; 2022 Nov; 35(11):1740-1748. PubMed ID: 35773332
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical significance of programmed cell death-ligand expression in small bowel adenocarcinoma is determined by the tumor microenvironment.
    Hoshimoto A; Tatsuguchi A; Hamakubo R; Nishimoto T; Omori J; Akimoto N; Tanaka S; Fujimori S; Hatori T; Shimizu A; Iwakiri K
    World J Gastroenterol; 2023 Oct; 29(40):5566-5581. PubMed ID: 37970475
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical, pathological genetics and intratumoral immune milieu of serrated adenocarcinoma of the colon.
    Yılmaz O; Crabbe A; Neyaz A; Pankaj A; Lee SH; Hosseini S; Rickelt S; Cerda S; Zhao Q; Leijsen L; Dineaux A; Shroff SG; Crotty R; Zhang ML; Yilmaz OH; Patil DT; Berger D; Deshpande V
    Histopathology; 2022 Sep; 81(3):380-388. PubMed ID: 35789111
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic value and clinicopathological roles of the tumor immune microenvironment in salivary duct carcinoma.
    Hirai H; Nakaguro M; Tada Y; Saigusa N; Kawakita D; Honma Y; Kano S; Tsukahara K; Ozawa H; Okada T; Okami K; Yamazaki K; Sato Y; Urano M; Kajiwara M; Utsumi Y; Shimura T; Fushimi C; Shimizu A; Kondo T; Imanishi Y; Sakai A; Sato Y; Togashi T; Hanazawa T; Matsuki T; Yamazaki K; Nagao T
    Virchows Arch; 2023 Sep; 483(3):367-379. PubMed ID: 37464232
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mismatch repair deficiency is associated with MSI phenotype, increased tumor-infiltrating lymphocytes and PD-L1 expression in immune cells in ovarian cancer.
    Xiao X; Dong D; He W; Song L; Wang Q; Yue J; Xie L
    Gynecol Oncol; 2018 Apr; 149(1):146-154. PubMed ID: 29496294
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High density of cytotoxic T-lymphocytes is linked to tumoral PD-L1 expression regardless of the mismatch repair status in colorectal cancer.
    Möller K; Blessin NC; Höflmayer D; Büscheck F; Luebke AM; Kluth M; Hube-Magg C; Zalewski K; Hinsch A; Neipp M; Mofid H; Lárusson H; Daniels T; Isbert C; Coerper S; Ditterich D; Rupprecht H; Goetz A; Bernreuther C; Sauter G; Uhlig R; Wilczak W; Simon R; Steurer S; Minner S; Burandt E; Krech T; Perez D; Izbicki JR; Clauditz TS; Marx AH
    Acta Oncol; 2021 Sep; 60(9):1210-1217. PubMed ID: 34092167
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antibodies Against Immune Checkpoint Molecules Restore Functions of Tumor-Infiltrating T Cells in Hepatocellular Carcinomas.
    Zhou G; Sprengers D; Boor PPC; Doukas M; Schutz H; Mancham S; Pedroza-Gonzalez A; Polak WG; de Jonge J; Gaspersz M; Dong H; Thielemans K; Pan Q; IJzermans JNM; Bruno MJ; Kwekkeboom J
    Gastroenterology; 2017 Oct; 153(4):1107-1119.e10. PubMed ID: 28648905
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MMR deficient undifferentiated/dedifferentiated endometrial carcinomas showing significant programmed death ligand-1 expression (sp 142) with potential therapeutic implications.
    Hacking S; Jin C; Komforti M; Liang S; Nasim M
    Pathol Res Pract; 2019 Oct; 215(10):152552. PubMed ID: 31353229
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Can evaluation of mismatch repair defect and TILs increase the number of triple-negative breast cancer patients eligible for immunotherapy?
    Özcan D; Lade-Keller J; Tramm T
    Pathol Res Pract; 2021 Oct; 226():153606. PubMed ID: 34530255
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Implications of LAG3 and CTLA4 immune checkpoints beyond PD-1/PD-L1 as a potential target in determining the prognosis of uveal melanoma patients.
    Kashyap S; Singh MK; Kumar N; Jha J; Lomi N; Meel R; Bakhshi S; Sen S; Singh L
    Br J Ophthalmol; 2024 May; 108(6):903-912. PubMed ID: 36918273
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PD-L1 Expression in Mismatch Repair-deficient Endometrial Carcinomas, Including Lynch Syndrome-associated and MLH1 Promoter Hypermethylated Tumors.
    Sloan EA; Ring KL; Willis BC; Modesitt SC; Mills AM
    Am J Surg Pathol; 2017 Mar; 41(3):326-333. PubMed ID: 27984238
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cytolytic activity correlates with the mutational burden and deregulated expression of immune checkpoints in colorectal cancer.
    Zaravinos A; Roufas C; Nagara M; de Lucas Moreno B; Oblovatskaya M; Efstathiades C; Dimopoulos C; Ayiomamitis GD
    J Exp Clin Cancer Res; 2019 Aug; 38(1):364. PubMed ID: 31429779
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.